Insider Selling: LeMaitre Vascular, Inc. (NASDAQ:LMAT) Director Sells 5,025 Shares of Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Director David B. Roberts sold 5,025 shares of the company’s stock in a transaction on Monday, May 6th. The stock was sold at an average price of $75.62, for a total value of $379,990.50. Following the transaction, the director now directly owns 14,114 shares in the company, valued at approximately $1,067,300.68. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

LeMaitre Vascular Stock Down 1.2 %

Shares of NASDAQ LMAT traded down $0.90 during trading hours on Wednesday, hitting $75.00. The company had a trading volume of 109,442 shares, compared to its average volume of 122,731. The firm’s 50 day moving average is $66.47 and its 200-day moving average is $59.23. The stock has a market capitalization of $1.68 billion, a P/E ratio of 49.67, a price-to-earnings-growth ratio of 2.99 and a beta of 0.88. LeMaitre Vascular, Inc. has a 1-year low of $44.27 and a 1-year high of $76.24.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 EPS for the quarter, beating the consensus estimate of $0.39 by $0.05. The business had revenue of $53.48 million for the quarter, compared to the consensus estimate of $51.50 million. LeMaitre Vascular had a net margin of 16.99% and a return on equity of 11.57%. LeMaitre Vascular’s revenue was up 13.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.27 earnings per share. On average, sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.77 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 30th. Investors of record on Thursday, May 16th will be issued a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.85%. The ex-dividend date is Wednesday, May 15th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 42.38%.

Analyst Ratings Changes

Several research firms recently issued reports on LMAT. Barrington Research raised their price target on LeMaitre Vascular from $69.00 to $79.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. StockNews.com upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. JMP Securities increased their price objective on LeMaitre Vascular from $72.00 to $77.00 and gave the stock a “market outperform” rating in a report on Friday, May 3rd. KeyCorp began coverage on LeMaitre Vascular in a research report on Tuesday, February 6th. They issued a “sector weight” rating on the stock. Finally, Stifel Nicolaus raised LeMaitre Vascular from a “hold” rating to a “buy” rating and upped their price target for the stock from $59.00 to $75.00 in a research report on Friday, April 26th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, LeMaitre Vascular has a consensus rating of “Moderate Buy” and an average target price of $73.83.

Hedge Funds Weigh In On LeMaitre Vascular

Several institutional investors and hedge funds have recently added to or reduced their stakes in LMAT. Shaker Investments LLC OH lifted its stake in shares of LeMaitre Vascular by 1.3% in the 1st quarter. Shaker Investments LLC OH now owns 13,658 shares of the medical instruments supplier’s stock valued at $906,000 after acquiring an additional 169 shares during the last quarter. Exchange Traded Concepts LLC raised its position in LeMaitre Vascular by 0.8% in the fourth quarter. Exchange Traded Concepts LLC now owns 23,656 shares of the medical instruments supplier’s stock valued at $1,343,000 after purchasing an additional 187 shares during the last quarter. Riverwater Partners LLC boosted its stake in shares of LeMaitre Vascular by 2.5% during the fourth quarter. Riverwater Partners LLC now owns 8,216 shares of the medical instruments supplier’s stock valued at $466,000 after purchasing an additional 198 shares in the last quarter. Albion Financial Group UT grew its holdings in shares of LeMaitre Vascular by 5.6% during the first quarter. Albion Financial Group UT now owns 3,974 shares of the medical instruments supplier’s stock worth $264,000 after purchasing an additional 212 shares during the last quarter. Finally, Texas Permanent School Fund Corp increased its stake in shares of LeMaitre Vascular by 1.3% in the first quarter. Texas Permanent School Fund Corp now owns 17,341 shares of the medical instruments supplier’s stock valued at $1,151,000 after buying an additional 225 shares during the period. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.